ABVC BioPharma, Inc. (NASDAQ: ABVC) announced the closing of a private placement of original issue discount senior convertible promissory notes with institutional and other accredited investors, generating aggregate gross proceeds of approximately $3.39 million before placement agent fees and other offering expenses. The announcement was made via NEWMEDIAWIRE.
The notes carry an aggregate principal amount of $4,106,060 and a 17.5% original issue discount, with a maturity date of June 30, 2027. Following the eight-month anniversary of the issuance date, the notes become convertible into shares of the Company's common stock at a conversion price equal to 85% of the average of the three volume-weighted average prices for the three trading days immediately prior to the date of conversion, subject to a floor price and adjustments as provided in the agreements.
ABVC expects to use the net proceeds for general working capital purposes, the funding of its subsidiaries, and to make a $625,000 settlement payment to Lind Global Fund II LP pursuant to a definitive release and settlement agreement. The company stated that this payment is expected to satisfy specified outstanding payment claims and support its ability to pursue broader financing and business development initiatives.
The offering is expected to support ABVC's broader strategy of advancing its pharmaceutical and medical-device portfolio through strategic licensing, subsidiary development, and independent financing initiatives. ABVC has established dedicated business platforms across its principal development areas, including AiBtl BioPharma Inc. for central nervous system drug programs, OncoX BioPharma for oncology, ForSeeCon Eye for ophthalmic medical-device development and commercialization, and BioKey (Cayman), Inc. for contract pharmaceutical development and manufacturing services as well as its AI Biotechnology Innovation Platform. Through these arrangements, ABVC seeks to advance its development programs while creating opportunities for licensing revenues, milestone payments, future royalties, and equity value.
The company continues to evaluate potential strategic financing and capital-market opportunities for its affiliated businesses as a potential means to support their long-term development and commercialization objectives. WallachBeth Capital, Inc. acted as the placement agent in connection with the offering. Hunter Taubman Fischer & Li LLC acted as legal counsel to the Company, and Sichenzia Ross Ference Carmel LLP acted as counsel to the placement agent.
The notes and the shares of common stock issuable upon conversion have not been registered under the Securities Act of 1933, as amended, or any state securities laws, and until so registered may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Additional details regarding the notes and the transaction will be available in the Company's Current Report on Form 8-K, which will be filed with the U.S. Securities and Exchange Commission. The full release is available at www.newmediawire.com.
The financing matters to investors and the biopharmaceutical sector because it provides ABVC with near-term liquidity while resolving a specific outstanding claim. The settlement payment to Lind Global Fund II LP is expected to satisfy specified outstanding payment claims and support the company's ability to pursue broader financing and business development initiatives. However, the convertible structure carries potential dilution risk for existing shareholders, as conversion at a discount to market prices could increase the share count. The company's ability to advance its six drug candidates and the Vitargus® ophthalmic medical device will depend on how effectively it deploys the net proceeds and secures additional capital for its subsidiaries. For the broader market, the transaction illustrates how clinical-stage biopharma companies are using structured private placements to bridge funding gaps while pursuing licensing and subsidiary-level financing strategies.
